JNJ · News · 20260814N

Guidance / Outlook

JOHNSON & JOHNSON · 2026-08-14 · Importance 53 · Surprise 60

Third-party reporting says Johnson & Johnson raised its full-year 2026 sales and earnings guidance after its second-quarter 2026 results. The reported outlook improvement was driven by robust performance in the Innovative Medicine segment, including new product launches. The report also identified challenges in the MedTech business, creating a mixed segment-level outlook for the remainder of 2026.